学院2016年至2019年期间获批科技部重大新药创制国家科技重大专项6项;国家自然科学基金金重点项目1项,面上项目19项,青年项目21项,教育部新世纪优秀人才支持计划3项,江苏省自然科学基金项目13项,南京市新兴产业引导专项资金项目1项。
学院教师为主体参加或主持的研究项目分别获得国家科技进步二等奖1项,教育部科学技术一等奖1项,江苏省科技进步一等奖1项,科技进步二等奖1项。
学院成立以来,科研创收年年创新高,2019年学院总到账经费数达3780万元,人均到账经费接近80万。2017年至2019年学院纵向到账总经费约3636万元,横向到账总经费约5338万元,为我院学科的发展提供了坚实基础和可靠保证。
学院近年来部分高水平论文发表情况
校内作者 | 论文名称 | 期刊名称 | 我校排名 | 发表 时间 | 影响 因子 |
吴照球 | Snail1-dependent p53 repression regulates expansion and activity of tumor-initiating cells in breast cancer | Nature Cell Biology | 1 | 2016 | 18.7 |
彭娟娟 | Real-Time In Vivo Hepatotoxicity Monitoring Through Chromophore-Conjugated Photon-Upconverting Nanoprobes | Angewandte Chemie International Edition | 1 | 2017 | 11.709 |
刘金峰 | A coupled ionization-conformational equilibrium is required to understand the properties of ionizable residues in the hydrophobic interior of staphylococcal nuclease. | J. Am. Chem. Soc | 3 | 2018 | 13.858 |
赵灵之 | Independent of EPR Effect: A Smart Delivery Nanosystem for Tracking and Treatment of Nonvascularized Intra-abdominal Metastases | Advanced Functional Materials | 1 | 2018 | 13.325 |
吴照球 | A ZEB1/p53 signaling axis in stromal fibroblasts promotes mammary epithelial tumours | Nature Communications | 1 | 2019 | 11.878 |
王丽蕊 | YIPF6 Controls Sorting of FGF21 Into COPII Vesicles and Promotes Obesity | Proceedings of the National Academy of Sciences of the United States of America | 1 | 2019 | 9.412 |
赵灵之 | MTH1 Inhibitor Amplifies the Lethality of Reactive Oxygen Species to Tumor in Photodynamic Therapy | 1 | 2020 | 12.804 | |
吴照球 | Inactivating endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies | J Clin Invest | 1 | 2020 | 11.864 |
吴照球 | Endothelial ZEB1 promotes angiogenesis-dependent bone formation and reverses osteoporosis | Nature Communications | 1 | 2020 | 12.121 |
吴照球 | A potent CBP/p300-Snail interaction inhibitor suppresses tumor growth and metastasis in wild-type p53-expressing cancer | Science Advances | 1 | 2020 | 13.116 |
学院近年来专利申请和授权情况
年份 | 专利申请数 | 专利授权数 |
2017年 | 2 | 0 |
2018年 | 1 | 1 |
2019年 | 8 | 1 |